Send to

Choose Destination
See comment in PubMed Commons below
Vaccine. 2003 Jun 20;21(21-22):2758-60.

Immunogenicity of a new Salmonella Typhi Vi polysaccharide vaccine--vax-TyVi--in Cuban school children and teenagers.

Author information

Instituto Finlay, DACTA, Avenida 27 No. 19805, La Lisa, AP 16017, CP 11600 Ciudad de La Habana, Cuba.


A randomized, controlled, double blind study was carried out in Cuban children and teenagers aged 9-13 years to evaluate the immunogenicity of vax-TyVi-Salmonella Typhi Vi polysaccharide vaccine-with respect control vaccines. Serum samples were taken before and 21 days after the immunization, and ELISA was used for the determination of antibodies to Vi polysaccharide. Subjects who received vax-TyVi and TYPHIM Vi (Pasteur-Mérieux) showed seroconversion rates of 85.61 and 78.36%, respectively. The geometric mean titer (GMT) values for Vi antibodies induced after vaccination were 6.27 microg/ml (5.40-7.38 microg/ml) and 5.97 microg/ml (5.01-7.10 microg/ml), respectively. In contrast, subjects receiving the tetanus toxoid vaccine showed 0% seroconversion.

[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center